$0.80 EPS Expected for ArcelorMittal (MT); ABLYNX NV (ABLYF) Shorts Lowered By 31.12%

January 17, 2018 - By Vivian Park

ABLYNX NV (OTCMKTS:ABLYF) had a decrease of 31.12% in short interest. ABLYF’s SI was 941,800 shares in January as released by FINRA. Its down 31.12% from 1.37M shares previously. With 700 avg volume, 1345 days are for ABLYNX NV (OTCMKTS:ABLYF)’s short sellers to cover ABLYF’s short positions. It closed at $42.1 lastly. It is down 0.00% since January 17, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts expect ArcelorMittal (NYSE:MT) to report $0.80 EPS on February, 9.They anticipate $0.32 EPS change or 66.67% from last quarter’s $0.48 EPS. MT’s profit would be $791.33 million giving it 11.41 P/E if the $0.80 EPS is correct. After having $1.18 EPS previously, ArcelorMittal’s analysts see -32.20% EPS growth. The stock decreased 0.52% or $0.19 during the last trading session, reaching $36.52. About 536,860 shares traded. ArcelorMittal (NYSE:MT) has risen 67.93% since January 17, 2017 and is uptrending. It has outperformed by 51.23% the S&P500.

Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company has market cap of $3.20 billion. The firm develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. It currently has negative earnings. The Company’s clinical programs include caplacizumab, an anti-vWF Nanobody that is in Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, an anti-RSV Nanobody, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that is in Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus.

Among 16 analysts covering Arcelormittal (NYSE:MT), 12 have Buy rating, 1 Sell and 3 Hold. Therefore 75% are positive. Arcelormittal had 53 analyst reports since July 21, 2015 according to SRatingsIntel. The company was initiated on Wednesday, October 14 by Berenberg. JP Morgan upgraded the shares of MT in report on Friday, October 9 to “Overweight” rating. The stock of ArcelorMittal (NYSE:MT) earned “Buy” rating by Jefferies on Tuesday, July 18. The stock of ArcelorMittal (NYSE:MT) earned “Buy” rating by Goldman Sachs on Tuesday, April 12. Credit Suisse maintained ArcelorMittal (NYSE:MT) rating on Friday, March 24. Credit Suisse has “Outperform” rating and $15 target. As per Wednesday, August 5, the company rating was upgraded by ABN Amro. The stock of ArcelorMittal (NYSE:MT) earned “Sell” rating by UBS on Monday, December 19. The company was upgraded on Friday, August 19 by JP Morgan. The stock of ArcelorMittal (NYSE:MT) earned “Buy” rating by Cowen & Co on Wednesday, August 23. The rating was downgraded by Bank of America to “Sell” on Tuesday, June 6.

ArcelorMittal, together with its subsidiaries, owns and operates steel manufacturing and mining facilities. The company has market cap of $36.12 billion. The firm operates through five divisions: NAFTA, Brazil, Europe, ACIS, and Mining. It has a 9.52 P/E ratio. It produces finished and semi-finished steel products with various specifications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: